View in EDS

REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas.

Saved in:
Bibliographic Details
Title: REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas.
Authors: Picca A; Service de Neuro-oncologie, Institut de Neurologie, AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France; Sorbonne Université, Inserm, CNRS, UMR S 1127, Paris Brain Institute (ICM), Paris, France., Touat M; Service de Neuro-oncologie, Institut de Neurologie, AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France; Sorbonne Université, Inserm, CNRS, UMR S 1127, Paris Brain Institute (ICM), Paris, France., Belin L; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Département de Santé Publique, Unité de Recherche Clinique PSL-CFX, CIC-1901, AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France., Gourmelon C; Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Nantes, France., Harlay V; Department of Neuro-Oncology, AP-HM, University Hospital Timone, Marseille, France., Cuzzubbo S; Department of Neurology, Hôpital Saint-Louis, Université Paris Cité, APHP, Paris, France., Cohen-Jonathan Moyal E; Department of Radiotherapy, Oncopole Claudius Regaud, Cancer University Institute of Toulouse, Oncopole Paul Sabatier University, Toulouse III, Cancer Research Center of Toulouse (CRCT), Toulouse, France., Bronnimann C; Hôpital Saint-André Bordeaux, Centre Hospitalier Universitaire, Service d'Oncologie, 33000 Bordeaux, France., Di Stefano AL; Department of Neurology, Foch Hospital, 92150 Suresnes, France; Division of Neurosurgery, Spedali Riuniti di Livorno-USL Toscana Nord-Ovest, 57124 Livorno, Italy., Laurent I; Unité de Recherche Clinique PSL-CFX, CIC-1901, AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France., Lerond J; Sorbonne Université, Inserm, CNRS, UMR S 1127, Paris Brain Institute (ICM), Paris, France., Carpentier C; Sorbonne Université, Inserm, CNRS, UMR S 1127, Paris Brain Institute (ICM), Paris, France., Bielle F; Sorbonne Université, Inserm, CNRS, UMR S 1127, Paris Brain Institute (ICM), Paris, France; Department of Neuropathology, AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France., Ducray F; Department of Neuro-Oncology, East Group Hospital, Hospices Civils de Lyon, Lyon, France., Dehais C; Service de Neuro-oncologie, Institut de Neurologie, AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France; Sorbonne Université, Inserm, CNRS, UMR S 1127, Paris Brain Institute (ICM), Paris, France. Electronic address: caroline.dehais@aphp.fr.
Corporate Authors: POLA Network
Source: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2024 May; Vol. 202, pp. 114034. Date of Electronic Publication: 2024 Mar 22.
Publication Type: Clinical Trial, Phase II; Journal Article
Journal Info: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38537315
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Picca+A%22">Picca A</searchLink>; Service de Neuro-oncologie, Institut de Neurologie, AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France; Sorbonne Université, Inserm, CNRS, UMR S 1127, Paris Brain Institute (ICM), Paris, France.<br /><searchLink fieldCode="AU" term="%22Touat+M%22">Touat M</searchLink>; Service de Neuro-oncologie, Institut de Neurologie, AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France; Sorbonne Université, Inserm, CNRS, UMR S 1127, Paris Brain Institute (ICM), Paris, France.<br /><searchLink fieldCode="AU" term="%22Belin+L%22">Belin L</searchLink>; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Département de Santé Publique, Unité de Recherche Clinique PSL-CFX, CIC-1901, AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France.<br /><searchLink fieldCode="AU" term="%22Gourmelon+C%22">Gourmelon C</searchLink>; Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Nantes, France.<br /><searchLink fieldCode="AU" term="%22Harlay+V%22">Harlay V</searchLink>; Department of Neuro-Oncology, AP-HM, University Hospital Timone, Marseille, France.<br /><searchLink fieldCode="AU" term="%22Cuzzubbo+S%22">Cuzzubbo S</searchLink>; Department of Neurology, Hôpital Saint-Louis, Université Paris Cité, APHP, Paris, France.<br /><searchLink fieldCode="AU" term="%22Cohen-Jonathan+Moyal+E%22">Cohen-Jonathan Moyal E</searchLink>; Department of Radiotherapy, Oncopole Claudius Regaud, Cancer University Institute of Toulouse, Oncopole Paul Sabatier University, Toulouse III, Cancer Research Center of Toulouse (CRCT), Toulouse, France.<br /><searchLink fieldCode="AU" term="%22Bronnimann+C%22">Bronnimann C</searchLink>; Hôpital Saint-André Bordeaux, Centre Hospitalier Universitaire, Service d'Oncologie, 33000 Bordeaux, France.<br /><searchLink fieldCode="AU" term="%22Di+Stefano+AL%22">Di Stefano AL</searchLink>; Department of Neurology, Foch Hospital, 92150 Suresnes, France; Division of Neurosurgery, Spedali Riuniti di Livorno-USL Toscana Nord-Ovest, 57124 Livorno, Italy.<br /><searchLink fieldCode="AU" term="%22Laurent+I%22">Laurent I</searchLink>; Unité de Recherche Clinique PSL-CFX, CIC-1901, AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France.<br /><searchLink fieldCode="AU" term="%22Lerond+J%22">Lerond J</searchLink>; Sorbonne Université, Inserm, CNRS, UMR S 1127, Paris Brain Institute (ICM), Paris, France.<br /><searchLink fieldCode="AU" term="%22Carpentier+C%22">Carpentier C</searchLink>; Sorbonne Université, Inserm, CNRS, UMR S 1127, Paris Brain Institute (ICM), Paris, France.<br /><searchLink fieldCode="AU" term="%22Bielle+F%22">Bielle F</searchLink>; Sorbonne Université, Inserm, CNRS, UMR S 1127, Paris Brain Institute (ICM), Paris, France; Department of Neuropathology, AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France.<br /><searchLink fieldCode="AU" term="%22Ducray+F%22">Ducray F</searchLink>; Department of Neuro-Oncology, East Group Hospital, Hospices Civils de Lyon, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Dehais+C%22">Dehais C</searchLink>; Service de Neuro-oncologie, Institut de Neurologie, AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France; Sorbonne Université, Inserm, CNRS, UMR S 1127, Paris Brain Institute (ICM), Paris, France. Electronic address: caroline.dehais@aphp.fr.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22POLA+Network%22">POLA Network</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229005373%22">European journal of cancer (Oxford, England : 1990)</searchLink> [Eur J Cancer] 2024 May; Vol. 202, pp. 114034. <i>Date of Electronic Publication: </i>2024 Mar 22.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Science+Ltd%22">Elsevier Science Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9005373 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1879-0852 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209598049%22">09598049 </searchLink><i>NLM ISO Abbreviation: </i>Eur J Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38537315
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.ejca.2024.114034
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 114034
    Titles:
      – TitleFull: REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Picca A
      – PersonEntity:
          Name:
            NameFull: Touat M
      – PersonEntity:
          Name:
            NameFull: Belin L
      – PersonEntity:
          Name:
            NameFull: Gourmelon C
      – PersonEntity:
          Name:
            NameFull: Harlay V
      – PersonEntity:
          Name:
            NameFull: Cuzzubbo S
      – PersonEntity:
          Name:
            NameFull: Cohen-Jonathan Moyal E
      – PersonEntity:
          Name:
            NameFull: Bronnimann C
      – PersonEntity:
          Name:
            NameFull: Di Stefano AL
      – PersonEntity:
          Name:
            NameFull: Laurent I
      – PersonEntity:
          Name:
            NameFull: Lerond J
      – PersonEntity:
          Name:
            NameFull: Carpentier C
      – PersonEntity:
          Name:
            NameFull: Bielle F
      – PersonEntity:
          Name:
            NameFull: Ducray F
      – PersonEntity:
          Name:
            NameFull: Dehais C
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: 2024 May
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1879-0852
          Numbering:
            – Type: volume
              Value: 202
          Titles:
            – TitleFull: European journal of cancer (Oxford, England : 1990)
              Type: main
ResultId 1